跳至主要内容
临床试验/NCT03762824
NCT03762824已完成4 期

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.

Region Skane0 个研究点目标入组 300 人开始时间: 2016年6月14日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Region Skane
入组人数
300
主要终点
2-fold rise in pneumococcal serotype-specific antibody concentration

研究概览

简要总结

The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited by pneumococcal vaccination using 13-valent conjugate vaccine in combined schedules with 23-valent polysaccharide vaccine. In addition, the aim is to study the clinical aspects of vaccination regarding: tolerability in immunosuppressed patients with IRD, impact on existing rheumatic disease, possible association with onset of new autoimmune diseases, long-term immunity following pneumococcal vaccination and efficacy in preventing invasive pneumococcal disease. Results from this study are expected to bridge the existing knowledge gap and contribute to body of evidence needed for recommendations and implementation of vaccination program in IRD patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients with IRD receiving active anti-rheumatic treatments with DMARDs or biological remedies are offered to participate in the study. The protocol permits stratification for prednisolone usage.

排除标准

  • known allergy/intolerance of pneumococcal vaccine
  • pregnancy
  • active infection

结局指标

主要结局

2-fold rise in pneumococcal serotype-specific antibody concentration

时间窗: 8 weeks after pneumococcal conjugate vaccine and 4-6 weeks after polysaccharide vaccination

Pneumococcal serotype-specific antibody concentration (12-valent)

次要结局

  • Long-term serotype-specific immunity to pneumococcal disease(3 years after vaccination)
  • Functional antibody response(8 weeks after pneumococcal conjugate vaccine and 4-6 weeks after polysaccharide vaccination)

研究者

发起方
Region Skane
申办方类型
Other
责任方
Sponsor

相似试验